title: [Comparison of antibody persistence between live attenuated and inactivated hepatitis A vaccines].
abstract: OBJECTIVE
  To study the antibody persistence of live attenuated hepatitits A vaccine, and to compare the antibody between with inactivated vaccine.
  
  
  METHODS
  211 HAV susceptible children were divided randomly into three groups, Group A was injected three doses HepA-L at 0, 6 and 12 monthes; Group B was administrated two dose HepA-L at 0 and 6 months, and group C was immunized with inactivated vaccine at month 0 and 6. Serum samples were detected for Anti-HAV at 1, 6, 7, 12, 13, 24, 84 months after vaccination in each group.
  
  
  RESULTS
  The seroconversion rates reached 100% after 2nd dose in all groups. The highest GMC was 2938.1 mlU/ml, founded in group C, and it was 1315.6 mlU/ml and 1586 mlU/ml in group A and B respectively. After the 3rd dose at month 12 in group A, the antibody increased dramatic, which reached 1945.3 mlU/ml. 84 months after first dose in each group, the antibody can be detected from all subjects. Though the GMC in group A declined to 336.8 mlU/ml, it was significant higher than that in group B and C.
  
  
  CONCLUSIONS
  The good booster effect with HepA-L was well observed in a short-term. The immune response induced by 2 to 3 doses HepA-L could compete with inactivated hepatitis A vaccine. However, long-term effects of both vaccines need further study.
authors.affiliation: Zhengding County Hospital of Chinese, Zhengding 050800, Hebei, China.
authors.forename: Huai-Feng
authors.initials: HF
authors.lastname: Liu
authors.forename: Xin-Jiang
authors.initials: XJ
authors.lastname: Zhang
authors.forename: Jian-Li
authors.initials: JL
authors.lastname: Zhang
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D005260:Female; D006506:Hepatitis A / Q000276:immunology* / Q000821:virology; D035922:Hepatitis A Antibodies / Q000097:blood; D022362:Hepatitis A Vaccines / Q000008:administration & dosage / Q000276:immunology*; D017957:Hepatitis A Virus, Human / Q000276:immunology*; D006801:Humans; D007114:Immunization; D007117:Immunization, Secondary; D008297:Male; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000276:immunology
chemical_list: D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated